MN1 expression levels predict ATRA resistance and sensitivity in patients with AML. (A) EFS and (B) OS of patients with AML older than 60 years treated with standard chemotherapy with or without ATRA and stratified for MN1 expression above or below the median expression (Kaplan-Meier survival analysis; log-rank test).